Sex hormones unrelated to prostate cancer risk

Jan 29, 2008

Sex hormones circulating in the blood do not appear to be associated with prostate cancer risk, according to data from 18 prior studies. The analysis will be published online January 29 in the Journal of the National Cancer Institute.

Having high levels of male sex hormones, known as androgens, has long been hypothesized as a risk factor for prostate cancer. Nearly two dozen prospective studies have examined the relationship between circulating sex hormones and prostate cancer risk, but the results have been inconsistent.

Andrew Roddam, D.Phil., of the University of Oxford in England and colleagues at the Endogenous Hormones and Prostate Cancer Collaborative Group collected the original data from 18 studies and analyzed it to determine the relationship between blood levels of sex hormones and prostate cancer. The pooled data included 3,886 men with prostate cancer and 6,438 controls.

The researchers found no association between prostate cancer risk and blood levels of different forms of testosterone or estrogen.

“The results of this collaborative analysis of the existing worldwide data on the associations between endogenous hormone concentrations and prostate cancer risk indicate that circulating concentrations of androgens and [estrogens] do not appear to be associated with the risk of prostate cancer,” the authors write.

In an accompanying editorial, Paul Godley, M.D., Ph.D., and colleagues at the University of North Carolina at Chapel Hill commend the authors for collaborating on this analysis, and they encourage researchers to use the results as an opportunity to shift the focus of prostate cancer research.

“The study obliges the scientific community to move past a seductive, clinically relevant, and biologically plausible hypothesis and get on with the difficult task of exploring, analyzing, and characterizing modifiable risk factors for prostate cancer,” the editorialists write.

Source: Journal of the National Cancer Institute

Explore further: New cancer drug target involving lipid chemical messengers

add to favorites email to friend print save as pdf

Related Stories

Chlordecone exposure and risk of prostate cancer

Jun 22, 2010

In an article to be published on 21 June 2010 in the Journal of Clinical Oncology, researchers from Inserm (Inserm unit 625 - Research Group on Human and Mammalian Reproduction, University of Rennes 1), the CHU (University Hospit ...

Infertility increases a man's risk of prostate cancer

Mar 22, 2010

Infertile men have an increased risk of developing high grade prostate cancer, which is more likely to grow and spread quickly. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journa ...

Prostate cancer therapy can increase heart risk factors

Feb 02, 2010

Androgen-deprivation therapy (ADT), commonly used to treat prostate cancer, can worsen heart risk factors and may increase the risk of heart attack and/or cardiac death, although the relationship between ADT and heart attack ...

Recommended for you

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

SDMike
not rated yet Jan 29, 2008
WOW! So much for "obvious factor" and "common sense" (quotes from prior research). Does this give the green light for older guys to use andro-supplements?